ACR25 Best Abstracts - Day 3 Save

Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025.  Below are several of the best abstracts from Day 3, as chosen by our outstanding faculty.

#ACR25 How hard will you go & at what cost? A study in China using CD20/BCMA Bispecific autologous CAR-T showed profound depletion, normalisation of abs and good response in #SLE (10/11 had LN). But 2 had G3 infections & cytopenia. Presenters said some had IVIG @RheumNow #ACRBest pic.twitter.com/TF0wpib5rr

— Md Yuzaiful Md Yusof (@Yuz6Yusof) October 28, 2025

Key slide and takeaways on the ACR 2025 extrarenal SLE guideline. Presented by Lisa Sammaritano @RheumNow #ACR25 #ACRBest pic.twitter.com/Xa97O6RdBY

— Antoni Chan MD (Prof) (@synovialjoints) October 27, 2025

Late breaking: secukinumab out-performs ustekinumab in PsA pt who have failed TNF therapy

RCT of 119 pt 
57.1% response at wk 28 in SEC 
27% response at wk 28 in UST

Numerically lower adverse events leading to d/c in SEC @RheumNow #ACR25 #ACRBest Abst LB06 pic.twitter.com/wDxtscP2ku

— Brian Jaros, MD (@Dr_Brian_MD) October 28, 2025

Plenary 3, HCQ blood levels in SLE 

HCQ level > 1150: 1.9x risk of HCQ toxicity
HCQ level < 750: 1.4x risk of active SLE 
HCQ dose < 5mg/kg: 1.9x risk active SLE

My take home? Blindly reducing dose to <5mg/kg is BAD; use levels instead!@RheumNow #ACRBest #ACR25 Abstr1722 pic.twitter.com/UCBPAKAyon

— Mike Putman (@EBRheum) October 28, 2025

#ACR25 Abstr#LB11 2025 belongs to Sjogren! In patients with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met primary endpoint; change in ESSDAI vs PBO. ESSPRI improved too! 

Wow! That PBO response was a flat line! Will need Global study @RheumNow #ACRBest pic.twitter.com/LXxpBZPCtF

— Md Yuzaiful Md Yusof (@Yuz6Yusof) October 28, 2025